Clinical Trial

A Study of Fosmanogepix in Healthy Adult Chinese Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study was to investigate the pharmacokinetics and safety of the investigational drug fosmanogepix including its active moiety manogepix following a single dose and multiple doses (by intravenous infusion (IV) or orally) in healthy Chinese adults. The study consisted of 2 consecutive Parts (Part-1, single-dose part followed by Part-2, multiple-dose part) including a total of 54 subjects (32 subjects in Part-1 and 22 subjects in PART-2) randomized.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-06; most recent amendment 2026-03-17.
Status change: Active, Not Recruiting → Completed 2025-08-05
Status change: Recruiting → Active, Not Recruiting 2025-07-02
Trial Details
NCT Number NCT06961708
Lead Sponsor Basilea Pharmaceutica
Collaborators: Biomedical Advanced Research and Development Authority
Conditions Healthy
Enrollment 54 participants
Start Date 2025-04-14
Primary Completion 2025-07-15 (estimated)
Study Completion 2025-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-06